Xanthohumol exhibits anti-myeloma activity in vitro through inhibition of cell proliferation, induction of apoptosis via the ERK and JNK-dependent mechanism, and suppression of sIL-6R and VEGF production - Sławińska-Brych, Adrianna; Zdzisińska, Barbara; Czerwonka, Arkadiusz; Mizerska-Kowalska, Magdalena; Dmoszyńska-Graniczka, Magdalena; Stepulak, Andrzej; Gagoś, Mariusz (Biochimica et biophysica acta. General subjects, 2019)
Keywords: acetylcysteine; antineoplastic activity; Apoptosis; Apoptosis - drug effects; caspase-3; cell cycle; Cell Line, Tumor; cell lines; cell proliferation; Cell Proliferation - drug effects; cyclins; cytotoxicity; enzyme inhibitors; enzyme-linked immunosorbent assay; Flavonoids - pharmacology; flow cytometry; fluorescence; Humans; immunoblotting; MAP Kinase Kinase 4 - metabolism; MAP Kinase Signaling System - drug effects; MAPKs; mitochondria; mitogen-activated protein kinase; Multiple myeloma; Multiple Myeloma - drug therapy; Multiple Myeloma - metabolism; Multiple Myeloma - pathology; myeloma; Neoplasm Proteins - metabolism; Propiophenones - pharmacology; protein synthesis; Receptors, Interleukin-6 - metabolism; ROS; signal transduction; sIL-6R; staining; therapeutics; Vascular Endothelial Growth Factor A - metabolism; vascular endothelial growth factors; VEGF; viability; Xanthohumol; Xanthohumol; VEGF; sIL-6R; Multiple myeloma; ROS; Apoptosis; MAPKs